Nilotinib hydrochloride - Generic Drug Details

What are the generic sources for nilotinib hydrochloride and what is the scope of freedom to operate?

Nilotinib hydrochloride is the generic ingredient in two branded drugs marketed by Apotex and Novartis, and is included in two NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Nilotinib hydrochloride has two hundred and thirty-one patent family members in fifty countries.

There are seven drug master file entries for nilotinib hydrochloride. Two suppliers are listed for this compound.

Summary for nilotinib hydrochloride

International Patents:	231
US Patents:	6
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	51
Clinical Trials:	204
Patent Applications:	264
DailyMed Link:	nilotinib hydrochloride at DailyMed

Recent Clinical Trials for nilotinib hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
United States Department of Defense	PHASE1
Medical University of South Carolina	PHASE1
Columbia University	PHASE1

See all nilotinib hydrochloride clinical trials

Pharmacology for nilotinib hydrochloride

Drug Class	Kinase Inhibitor
Mechanism of Action	Bcr-Abl Tyrosine Kinase Inhibitors Cytochrome P450 2B6 Inducers Cytochrome P450 2C8 Inducers Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors P-Glycoprotein Inhibitors UGT1A1 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for nilotinib hydrochloride

L01EA	BCR-ABL tyrosine kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for NILOTINIB HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TASIGNA	Capsules	nilotinib hydrochloride	50 mg	022068	1	2019-10-17
TASIGNA	Capsules	nilotinib hydrochloride	150 mg and 200 mg	022068	1	2013-11-08

US Patents and Regulatory Information for nilotinib hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	AB	RX	Yes	No
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-002	Jun 17, 2010	AB	RX	Yes	No	8,389,537*PED				Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-002	Jun 17, 2010	AB	RX	Yes	No	8,415,363*PED				Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	AB	RX	Yes	No
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007	AB	RX	Yes	Yes
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-002	Jun 17, 2010	AB	RX	Yes	No	8,293,756*PED				Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007	AB	RX	Yes	Yes

Expired US Patents for nilotinib hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	7,169,791*PED
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007	7,169,791*PED
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-002	Jun 17, 2010	7,169,791*PED

International Patents for nilotinib hydrochloride

Country	Patent Number	Title	Estimated Expiration
Ukraine	94234	КРИСТАЛІЧНА ФОРМА 4-МЕТИЛ-N-[3-(4-МЕТИЛІМІДАЗОЛ-1-ІЛ)-5-ТРИФТОРМЕТИЛФЕНІЛ]-3-(4-ПІРИДИН-3-ІЛПІРИМІДИН-2-ІЛАМІНО)-БЕНЗАМІДУ[КРИСТАЛЛИЧЕСКАЯ ФОРМА 4-МЕТИЛ-N-[3-(4-МЕТИЛИМИДАЗОЛ-1-ИЛ)-5-ТРИФТОРМЕТИЛФЕНИЛ]-3-(4-ПИРИДИН-3-ИЛПИРИМИДИН-2-ИЛАМИНО)-БЕНЗАМИДА (CRYSTALLINE FORMS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE)
Taiwan	I428333
Canada	2615669	SELS DE 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE (SALTS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE)
Slovenia	2284167
Hungary	E031791
Spain	2386974
New Zealand	599968	Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity

Market Dynamics and Financial Trajectory for Nilotinib Hydrochloride

Last updated: August 18, 2025

Introduction

Nilotinib hydrochloride is a selective BCR-ABL tyrosine kinase inhibitor primarily prescribed for chronic myeloid leukemia (CML). Approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) in 2007, it has established itself within the oncology therapeutics landscape. As the pharmaceutical sector evolves with innovation, patent protection cycles, and strategic market expansions, understanding the market dynamics and financial trajectory of nilotinib hydrochloride becomes critical for stakeholders ranging from healthcare providers to investors.

Market Overview

The global nilotinib hydrochloride market encompasses sales derived from its primary indication—CML management—and potential off-label applications. The market is driven by increasing CML prevalence, technological advancements in targeted therapies, and the strategic positioning of key pharmaceutical players.

Epidemiological Drivers

CML accounts for approximately 15-20% of adult leukemia cases worldwide. According to the Globocan 2020 report, cancer incidences, including CML, are rising due to aging populations and improved diagnostic capabilities, directly boosting demand for effective therapies such as nilotinib. The International Agency for Research on Cancer projects a CAGR of 4.5% in CML diagnoses globally over the next decade.

Competitive Landscape

Novartis’s Glivec (imatinib) was the first BCR-ABL inhibitor, but the advent of nilotinib has provided a more potent alternative, especially for patients resistant to first-line agents. Chemo- and targeted therapy drug development strategies have led to the emergence of second-generation inhibitors, with nilotinib occupying a strategic niche due to its efficacy and safety profile.

Key players include:

• Novartis: Market leader with patent-protected formulations.
• Emerging biotech firms: Developing biosimilars and generics post-patent expiry.
• Generic manufacturers: Extending market reach, especially in emerging markets.

Market Dynamics

1. Patent Life Cycle and Market Exclusivity

Novartis's patent protections for nilotinib encapsulate a significant portion of its market exclusivity, anticipated to expire around late 2020s. As patents lapse, generics are expected to enter, intensifying market competition and exerting downward pressure on prices. This dynamic is pivotal for the financial trajectory, influencing revenue streams.

2. Regulatory Approvals and Expanded Indications

While initially approved for CML, ongoing clinical trials explore nilotinib’s efficacy in other hematologic disorders, such as Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Regulatory approval for new indications can enhance sales, diversify revenue sources, and mitigate patent expiration impacts.

3. Pricing and Reimbursement Policies

Pricing strategies vary geographically. Developed markets such as the U.S. and Europe see premium pricing due to high R&D costs and reimbursement mechanisms favoring innovative drugs. Conversely, emerging markets implement price controls and subsidized programs, affecting overall revenue. Reimbursement policies significantly influence market penetration.

4. Market Penetration and Adoption

Physician preference for second-generation inhibitors like nilotinib over first-generation counterparts hinges on clinical efficacy, side effect profiles, and patient compliance. Increased adoption rates bolster sales volumes, especially where clinical guidelines favor targeted therapies.

5. Impact of Biosimilars and Generics

The entry of biosimilars, following patent timelines, poses a substantial threat to revenues. Market analysts project that biosimilar nilotinib could capture up to 60% of the market share within 5 years post-patent expiry, significantly impacting Novartis’s profitability.

6. Strategic Collaborations and Licensing

Partnerships with regional distributors and licensing agreements enable market expansion into emerging economies, crucial for sustaining revenue growth amid patent expirations.

Financial Trajectory Analysis

Revenue Trends

Pre-Patent Expiry: Nilotinib’s revenues have steadily increased, driven by robust global sales, strategic marketing, and expanding indications. Novartis reported that in 2021, nilotinib contributed approximately USD 1.8 billion, representing roughly 7% of its oncology portfolio revenues.

Post-Patent Expiry: Anticipated patent expiration in the late 2020s is likely to lead to revenue erosion unless offset by biosimilar sales, increased volumetric sales in emerging markets, or new indications.

Profitability Metrics

Gross margins on nilotinib have been high (~85%) due to the high R&D costs amortized over a protected market. However, margins are expected to decline post-patent, influenced by competitive pricing and generic substitution. Strategic cost management and portfolio diversification will be essential for maintaining profitability.

Future Market Share and Revenue Projections

Market forecasts suggest:

• 2023–2028: Compound annual growth rate (CAGR) of approximately 4% in global nilotinib sales.
• 2028 onward: A decline of 20–30% in revenues due to biosimilar competition if no new indications are approved or pipeline products introduced.

Potential Upside: Approval of nilotinib for additional indications could slow decline, with some projections indicating a plateau or slight uptick in revenues.

Market Challenges and Opportunities

Challenges

• Patent cliff and biosimilar competition: Eroding exclusivity.
• Pricing pressures: Especially in cost-sensitive markets.
• Regulatory hurdles: For new indications and biosimilar approvals.
• Competitive alternatives: Other second-generation TKIs like dasatinib and bosutinib.

Opportunities

• Development of biosimilars: To capture market share post-patent expiry.
• Expansion into emerging markets: With cost-effective generic options.
• Pipeline innovations: Creating next-generation inhibitors or combination therapies.
• Pharmacogenomics: Personalizing therapy to improve outcomes and reduce costs.

Conclusion

The market for nilotinib hydrochloride remains dynamic, driven by epidemiological shifts, strategic patent management, and evolving therapeutic landscapes. Revenue growth is robust in the near term, bolstered by global CML prevalence and continued clinical gains. However, the impending patent expiration and advent of biosimilars pose significant challenges, prompting pharmaceutical companies to innovate and diversify their portfolios.

Investment and strategic decisions around nilotinib’s future hinge on regulatory developments, pipeline advancements, and competitive positioning, with opportunities in biosimilar manufacturing, pipeline expansion, and market penetration in emerging economies.

Key Takeaways

• Market dominance is currently maintained by patent protection, but imminent expiration will catalyze biosimilar entry.
• Increased CML diagnosis globally supports sustained demand; however, pricing pressures and competition require strategic management.
• Expanding indications and pipeline innovations are critical for revenue stabilization in post-patent scenarios.
• Emerging markets present significant growth avenues due to affordability and increasing healthcare infrastructure.
• Proactive adaptation to biosimilar and generic threats, combined with strategic collaborations, can sustain profitability.

FAQs

1. When is the patent for nilotinib hydrochloride expected to expire?
Patent protections for nilotinib held by Novartis are anticipated to lapse in the late 2020s, generally around 2025-2028, depending on jurisdictional patent extensions and legal challenges.

2. What are the primary competitors to nilotinib in CML treatment?
First-generation imatinib remains a competitor, alongside second-generation TKIs like dasatinib, bosutinib, and the third-generation agent ponatinib, each with distinct efficacy and safety profiles.

3. How does the entry of biosimilars impact the nilotinib market?
Biosimilars are expected to significantly reduce costs and market share for original formulations, with projections indicating up to 60% market capture within five years post-patent expiry.

4. Are there ongoing clinical trials for new indications of nilotinib?
Yes, trials are exploring nilotinib's efficacy in off-label uses such as other hematologic malignancies, which could expand its therapeutic footprint if approved.

5. What strategies can pharmaceutical companies adopt to mitigate revenue loss from patent expiration?
Companies may develop biosimilars, diversify into new indications, strengthen market presence in emerging economies, and innovate with combination therapies to sustain revenues.

---

Sources

[1] Globocan 2020. International Agency for Research on Cancer.
[2] Novartis Annual Reports (2021).
[3] FDA Drug Approval Database.
[4] MarketResearch.com. "Global Oncology Drug Market Outlook."
[5] ClinicalTrials.gov. "Studies on Nilotinib in Hematology."